Anastassis Perrakis

The Netherlands Cancer Institute, Oncode Institute

Papers

2

Total Citations

12

H-Index

2

About

Anastassis Perrakis is a structural biologist whose research sits at the intersection of protein biophysics and fragment-based drug discovery. His most recognized work focuses on the application of biophysical screening technologies, particularly nano-Differential Scanning Fluorimetry (nano-DSF), a thermal shift assay approach that measures how a target protein's melting temperature responds to changes in its chemical environment — including the binding of small molecular fragments. This technique has become an increasingly valuable tool in early-stage drug discovery pipelines, enabling researchers to identify promising fragment hits with greater efficiency and sensitivity. Perrakis's contributions have helped establish nano-DSF as a reliable and practical method within fragment-based lead discovery workflows, bridging the gap between structural characterization and medicinal chemistry. His 2021 publications on this topic have already begun accumulating citations within the research community, reflecting growing interest in accessible, high-throughput biophysical methods. For students and researchers working in structural biology, chemical biology, or drug discovery, Perrakis's work offers both methodological guidance and conceptual grounding in how modern biophysical tools can accelerate the identification of therapeutically relevant protein-ligand interactions.

Research Focus

Key Achievements

2
H-Index
2
Papers
12
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
7 citations · 2021
📈 Most Prolific Year: 2021 (2 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: The Netherlands Cancer Institute, Oncode Institute

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 7 days ago